XML 69 R59.htm IDEA: XBRL DOCUMENT
v3.26.1

Research and Development Funding Expense - R&D Funding Arrangements (Details) - USD ($) $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2026 | Mar. 31, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Total Commitments | $ 825,000 |
Unfunded Commitments | 600,000 |
Research and development funding expense | 39,790 | $ 50,500
Phase 2b, TEV-408 |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Research and development funding expense | 14,300 |
Johnson & Johnson | JNJ‑4804 |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Total Commitments | 500,000 |
Unfunded Commitments | 500,000 |
Teva Pharmaceuticals | Total Funding, TEV-408 |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Total Commitments | 75,000 |
Unfunded Commitments | 75,000 |
Research and development commitment | 500,000 |
Teva Pharmaceuticals | Phase 2b, TEV-408 |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Research and development commitment | 75,000 |
Teva Pharmaceuticals | Phase 3, TEV-408 |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Research and development commitment | 425,000 |
Biogen | Litifilimab |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Total Commitments | 250,000 |
Unfunded Commitments | $ 25,000 |

X
- Definition Research and Development Commitment + References No definition available. + Details
Name: | rprx_ResearchAndDevelopmentCommitment
Namespace Prefix: | rprx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Commitments + References No definition available. + Details
Name: | rprx_ResearchAndDevelopmentCommitments
Namespace Prefix: | rprx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Unfunded Commitments + References No definition available. + Details
Name: | rprx_ResearchAndDevelopmentUnfundedCommitments
Namespace Prefix: | rprx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=rprx_Phase2bTEV408Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_JohnsonAndJohnsonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rprx_JNJ4804Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_TevaPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rprx_TotalFundingTEV408Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rprx_Phase3TEV408Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rprx_LitifilimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |